SELENBP1 and cancer: The expression of SELENBP1 mRNA was significantly lower in cancer specimens from patients with high-grade, locally advanced T stage (pT3/pT4), progression, and cancer-specific death than in those with low-grade, local disease (pT1/pT2) and nonprogression who survived or died of other causes than RCC (P = 0.042, P = 0.034, P = 0.009, and P = 0.002, respectively) (Table 3).